申请人:Actelion Pharmaceuticals Ltd.
公开号:US07727979B2
公开(公告)日:2010-06-01
The invention relates to guanidine derivatives of formula (I) where: A represents a chain of 3-6 carbon atoms, one of which can be replaced by —N(R′)— or —O— and R′ is H or a substituent; the ring skeleton only contains both double bonds of the thiazole component; the pharmaceutically-acceptable acid addition salts of basic compounds of formula (I), the pharmaceutically-acceptable salts of compounds of formula (I), comprising acid groups, with bases, the pharmaceutically-acceptable esters of hydroxy or carboxyl group containing compounds of formula (I) and the solvates or hydrates thereof, which exhibit a neuropeptide FF receptor antagonist effect. The above are suitable for the treatment of pain and hyperalgesia, withdrawal symptoms in alcohol, psychotropic and nicotine dependencies, for improvement or cure of said dependencies, for regulation of insulin excretion, food intake, memory functions, blood pressure, electrolyte and energy management and for treatment of urinary incontinence. The above can be produced using generally used methods and processed to give medicaments.
本发明涉及公式(I)的胍衍生物,其中:A代表一个由3-6个碳原子组成的链,其中一个可以被—N(R′)—或—O—所取代,而R′为H或取代基;环骨架仅包含噻唑酮组分的双键;公认为药用的酸加成盐的公式(I)的碱性化合物,公认为药用的含酸基的公式(I)的化合物与碱的盐,公认为药用的含羟基或羧基的公式(I)的酯以及其溶剂化合物或水合物,其表现出神经肽FF受体拮抗剂的效果。上述化合物适用于治疗疼痛和高敏感性、酒精、精神药物和尼古丁依赖的戒断症状,用于改善或治愈上述依赖症状,用于调节胰岛素分泌、食物摄入、记忆功能、血压、电解质和能量管理以及治疗尿失禁。上述化合物可以使用通常使用的方法制备,并加工成药物。